Innate Pharma, Institute for Follicular Lymphoma Collaborate to Study IPH6501 in Follicular Lymphoma

MT Newswires Live12-06

Innate Pharma (IPHA) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood cancer.

The company's ongoing phase 1/2 trial, which examines IPH6501 in relapsed/refractory non-hodgkin lymphoma, will now include patients with relapsed/refractory follicular lymphoma.

To support the inclusion of follicular lymphoma patients in the trial, the Institute for Follicular Lymphoma will initially invest $3 million into new shares of Innate.

The Institute for Follicular Lymphoma may invest an additional $4.9 million upon reaching certain milestones, the partners said.

Shares of Innate Pharma rose more than 12% in premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489067404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 17:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489067404","market":"nz","top_or_hot":-1,"title":"Innate Pharma, Institute for Follicular Lymphoma Collaborate to Study IPH6501 in Follicular Lymphoma","media":"MT Newswires Live","content":"<html><body><p> Innate Pharma (IPHA) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood cancer.</p><p>The company's ongoing phase 1/2 trial, which examines IPH6501 in relapsed/refractory non-hodgkin lymphoma, will now include patients with relapsed/refractory follicular lymphoma.</p><p>To support the inclusion of follicular lymphoma patients in the trial, the Institute for Follicular Lymphoma will initially invest $3 million into new shares of Innate.</p><p>The Institute for Follicular Lymphoma may invest an additional $4.9 million upon reaching certain milestones, the partners said.</p><p>Shares of Innate Pharma rose more than 12% in premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innate Pharma, Institute for Follicular Lymphoma Collaborate to Study IPH6501 in Follicular Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnate Pharma, Institute for Follicular Lymphoma Collaborate to Study IPH6501 in Follicular Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 17:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma (IPHA) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPHYF","symbol_name":"Innate Pharma","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489067404","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489067404","pubTimestamp":1733477233,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Innate Pharma (IPHA) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPHYF":"Innate Pharma","IPHA":"Innate Pharma SA","BK4139":"生物科技"},"translate_title":"Innate Pharma与滤泡性淋巴瘤研究所合作研究IPH6501治疗滤泡性淋巴瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPHYF":1,"IPHA":0.9},"content_text":"Innate Pharma (IPHA) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood cancer.The company's ongoing phase 1/2 trial, which examines IPH6501 in relapsed/refractory non-hodgkin lymphoma, will now include patients with relapsed/refractory follicular lymphoma.To support the inclusion of follicular lymphoma patients in the trial, the Institute for Follicular Lymphoma will initially invest $3 million into new shares of Innate.The Institute for Follicular Lymphoma may invest an additional $4.9 million upon reaching certain milestones, the partners said.Shares of Innate Pharma rose more than 12% in premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489067404"}